High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
作者信息
Neurath G B, Ambrosius D
出版信息
J Chromatogr. 1979 Jun 11;163(2):230-5. doi: 10.1016/s0378-4347(00)81470-x.
PMID:541378
Abstract
摘要
相似文献
1
High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
J Chromatogr. 1979 Jun 11;163(2):230-5. doi: 10.1016/s0378-4347(00)81470-x.
2
Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
J Chromatogr. 1983 Oct 14;277:191-9. doi: 10.1016/s0378-4347(00)84836-7.
3
Spironolactone response related to plasma canrenone concentration [proceedings].
Br J Clin Pharmacol. 1979 Apr;7(4):426P-427P.
4
Enhancement by food of canrenone bioavailability from spironolactone.
Clin Pharmacol Ther. 1977 Jul;22(1):100-3. doi: 10.1002/cpt1977221100.
5
Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
J Chromatogr. 1979 Apr 1;171:519-21. doi: 10.1016/s0021-9673(01)95350-6.
6
Is canrenone the major metabolite of spironolactone?
Clin Pharm. 1983 May-Jun;2(3):209-10.
7
Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
Clin Exp Hypertens A. 1983;5(2):239-48. doi: 10.3109/10641968309048824.
8
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Int J Clin Pharmacol Biopharm. 1977 May;15(5):205-10.
9
Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
Ther Drug Monit. 1990 Jan;12(1):82-4. doi: 10.1097/00007691-199001000-00015.
10
Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Clin Pharmacol Ther. 1976 Feb;19(2):177-82. doi: 10.1002/cpt1976192177.
Zotero 插件